PDF(Pubmed)
Abstract：
BACKGROUND: Sulfadoxine-pyrimethamine (SP), as a partner to artesunate as ACT is the treatment of choice for uncomplicated P. falciparum infections in the majority of India and SP-resistance has a potential to lead to ACT failure. In the lack of robust surveillance of therapeutic efficacy of SP, validate molecular markers of SP-resistance offer a hint of failing SP. However, studies reporting these validated markers often suffer from certain pitfalls that warrant a careful interpretation.
METHODS: Critical analyses of the results and their reported interpretations from a recent study and other studies conducted on the WHO-validated molecular markers of SP-resistance in India were analysed and the main problems with studying and reporting of these markers are presented here. It was noted that almost all studies analysed flawed either on the usage, estimation and/or interpretation of the standardized classification of the studies SP mutations. These flaws not only impart spatiotemporal incomparability of the published data but also have the potential of being misunderstood and wrongly translated.
CONCLUSIONS: Based on this universal problem in studying, reporting and interpreting the data from the studies on molecular markers of SP-resistance, it is stressed that the future studies should be conducted with utmost caution so that robust evidence may be generated and correctly translated to policy.
METHODS: Critical analyses of the results and their reported interpretations from a recent study and other studies conducted on the WHO-validated molecular markers of SP-resistance in India were analysed and the main problems with studying and reporting of these markers are presented here. It was noted that almost all studies analysed flawed either on the usage, estimation and/or interpretation of the standardized classification of the studies SP mutations. These flaws not only impart spatiotemporal incomparability of the published data but also have the potential of being misunderstood and wrongly translated.
CONCLUSIONS: Based on this universal problem in studying, reporting and interpreting the data from the studies on molecular markers of SP-resistance, it is stressed that the future studies should be conducted with utmost caution so that robust evidence may be generated and correctly translated to policy.
摘要：
背景：磺胺多辛-乙胺嘧啶（SP），作为青蒿琥酯的合作伙伴,ACT是印度大部分地区无并发症恶性疟原虫感染的首选治疗方法,而SP耐药有可能导致ACT失败.在缺乏对SP治疗效果的稳健监测的情况下，验证SP抗性的分子标记提供了SP失败的提示。然而,报告这些经过验证的标记物的研究通常会遇到某些陷阱，需要仔细解释。
方法：分析了最近的一项研究和其他研究对印度经WHO验证的SP抗性分子标记进行的结果及其报告的解释，并在此介绍了研究和报告这些标记的主要问题。有人指出，几乎所有的研究都分析了使用上的缺陷，研究SP突变的标准化分类的估计和/或解释。这些缺陷不仅赋予已发布数据的时空不可比性，而且有可能被误解和错误翻译。
结论：基于研究中的普遍问题，报告和解释来自SP抗性分子标记研究的数据，强调未来的研究应谨慎进行，以便产生有力的证据并正确转化为政策。
方法：分析了最近的一项研究和其他研究对印度经WHO验证的SP抗性分子标记进行的结果及其报告的解释，并在此介绍了研究和报告这些标记的主要问题。有人指出，几乎所有的研究都分析了使用上的缺陷，研究SP突变的标准化分类的估计和/或解释。这些缺陷不仅赋予已发布数据的时空不可比性，而且有可能被误解和错误翻译。
结论：基于研究中的普遍问题，报告和解释来自SP抗性分子标记研究的数据，强调未来的研究应谨慎进行，以便产生有力的证据并正确转化为政策。
